NPPA caps trade margins on 137 cancer drugs from November 9

India's drug price regulator has capped the trade margin on 137 anti-cancer medicines at 30%, a move the government expects to cut the retail price of some of these drugs by as much as 70%. The National Pharmaceutical Pricing Authority (NPPA) issued the order through a Gazette notification on October 17, 2026, and the new prices will take effect on November 9, 2026. Drug makers have seven days from the notification to tell the authority their revised maximum retail prices (MRPs). The cap covers non-scheduled formulations that contain any of the 137 listed drugs, alone or in combination, in any strength or form, including patented medicines.

Cancer treatment is one of the heaviest health costs an Indian family can face, and much of it is paid out of pocket. Many newer cancer medicines, especially the biologic and targeted drugs on this list, are sold at prices where the chain of distributors, stockists and retailers adds a large mark-up between the factory and the patient. Trade margin rationalisation does not set a fixed price for each drug. Instead, it limits how much that chain can add. Where margins were very wide, prices will fall steeply; where they were already modest, the change will be small.

This is why the government's figure is "up to" 70%, not a flat cut. A drug sold to distributors at a price close to its MRP will barely change; one with a wide gap between the two could fall sharply. The 2019 pilot gives a sense of the possible scale: when margins on 42 cancer drugs were capped, the MRPs of 526 brands fell by as much as 90%.

For the economy, the order is a targeted price control rather than a broad one. It touches a narrow, high-value segment of the medicines market, and it moves money from the trade channel to patients and insurers. Hospital pharmacies, which earn part of their income from medicines sold to in-patients, may see lower revenue on these drugs. Shares of several hospital chains and drug makers, including Max Healthcare, Apollo Hospitals, Sun Pharma and Dr Reddy's, traded lower after the announcement, according to market reports. Analysts have pointed out that a cap on trade margins does not automatically reduce what manufacturers earn, since it targets the mark-up after the drug leaves the factory.

There are practical questions still to be answered. Companies will need to re-label or re-price stock already in the supply chain before November 9, and the regulator will need to monitor compliance across thousands of pharmacies. Patients will feel the benefit only if retailers pass on the lower MRPs in full.

Short-term: From November 9, patients buying these medicines should pay less, in some cases far less. Drug companies, distributors and retailers must adjust prices and stock within weeks, and hospital chains may see a dent in pharmacy income.

Long-term: Lower prices could help more patients finish full courses of treatment and reduce the strain on family savings and health insurance. If the approach works, the government may extend trade margin caps to other high-cost medicines, as it has now done after the 2019 pilot.

Who is affected: Cancer patients and their families, health insurers, hospital pharmacies, chemists and distributors, and pharmaceutical companies that sell these drugs in India.

Questions and Answers